Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy-Reference-Cited by-同舟云学术

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy

Published:2021-09-08 Issue:3 Volume:65 Page:1770-1785
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Dilger Andrew K.¹,Pabbisetty Kumar B.¹^ORCID,Corte James R.¹^ORCID,De Lucca Indawati¹,Fang Tianan¹,Yang Wu¹,Pinto Donald J. P.¹^ORCID,Wang Yufeng¹,Zhu Yeheng¹,Mathur Arvind¹,Li Jianqing¹^ORCID,Hou Xiaoping¹^ORCID,Smith Daniel¹,Sun Dawn¹,Zhang Huiping¹,Krishnananthan Subramaniam¹,Wu Dauh-Rurng¹,Myers Joseph E.¹,Sheriff Steven¹,Rossi Karen A.¹,Chacko Silvi¹,Zheng Joanna J.¹,Galella Michael A.¹,Ziemba Theresa¹,Dierks Elizabeth A.¹,Bozarth Jeffrey M.¹,Wu Yiming¹,Crain Earl¹,Wong Pancras C.¹,Luettgen Joseph M.¹,Wexler Ruth R.¹,Ewing William R.¹^ORCID

Affiliation:

1. Research and Development, Bristol Myers Squibb Company, P.O. Box 5400, Princeton, New Jersey 08543, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00613

Reference45 articles.

1. New oral anticoagulants: A view from the laboratory

2. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

3. Thrombosis: a major contributor to the global disease burden